Cat: PA2000-9557

Recombinant Human MYEOV2 Protein,His

  • Price
  • Size
  • Number

    Order now. For delivery time, please consult customer service

  • Pre-sale guidance and worry-free after-sale service
  • Quality assurance for cold chain transportation

Analytical Data

  • 基因名

    MYEOV2

  • Application

    SPRMSTBLIITCELISA细胞实验药物筛选

  • 别名

    COPS9; MYEOV2; COP9 signalosome complex subunit 9; CSN acidic protein; CSNAP; Myeloma-overexpressed gene 2 protein

  • 种属

    Human

  • 表达系统

    E. coli

  • 标签

    His tag N-Terminus

  • 纯度

    Greater than 90% as determined by SDS-PAGE.

  • 蛋白编号

    Q8WXC6

  • 表达区间

    1-57 aa

  • 氨基酸序列

    MKPAVDEMFP EGAGPYVDLD EAGGSTGLLM DLAANEKAVH ADFFNDFEDL FDDDDIQ

  • 分子量

    6.2 kDa

  • 内毒素

    < 1.0 EU per μg protein as determined by the LAL method.

  • 性状

    Freeze-dried powder

  • 缓冲液

    PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.

  • 复溶方法

    Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.

  • 个性化定制

    点位突变 标签定制 buffer定制 全长蛋白定制

  • 稳定性测试

    The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.

  • 保存条件 & 期限

    Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

  • 运输条件

    In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.

Quality inspection process

Related Products

Protein Description

MYEOV2 (Myeloma Overexpressed 2) is a protein that has garnered attention in biomedical research due to its potential role in tumorigenesis and its involvement in various cancers, particularly multiple myeloma. Its overexpression has been linked to disease progression and poor prognosis, making it a significant target for therapeutic intervention and biomarker studies. Researchers have been investigating the functional mechanisms of MYEOV2, focusing on its interactions at the molecular level and how these contribute to cellular processes like proliferation, apoptosis, and immune evasion. The production of recombinant MYEOV2 protein is crucial for these studies, as it allows for detailed analysis of its biochemical properties, structural characteristics, and potential interactions with other molecules. By exploring the biochemical pathways influenced by MYEOV2 and its contribution to tumor pathology, researchers aim to uncover new therapeutic strategies that could harness this protein’s functions. Additionally, understanding MYEOV2's role could lead to the development of diagnostics that leverage its expression profiles, paving the way for personalized medicine approaches in cancer treatment. Overall, the research into MYEOV2 recombinant protein is pivotal for advancing our understanding of cancer biology and improving therapeutic outcomes for patients suffering from malignancies associated with this protein.

客服热线

027-8586 6806

E-mail

sales@ipodix.cn

人工客服①

汪经理

18007124176


加微信咨询

人工客服②

简经理

18164034885


加微信咨询
IPODIX North America (HQ)
Proteintech Group, Inc
5500 Pearl Street, Suite 400
Rosemont, IL 60018, USA
1-888-478-4522
proteintech@ptglab.com
IPODIX North America (HQ)
Proteintech Group, Inc
5500 Pearl Street, Suite 400
Rosemont, IL 60018, USA
1-888-478-4522
proteintech@ptglab.com
IPODIX North America (HQ)
Proteintech Group, Inc
5500 Pearl Street, Suite 400
Rosemont, IL 60018, USA
1-888-478-4522
proteintech@ptglab.com
  • 30000+

    Recombinant

  • 100+

    Researcher

  • 100+

    Countries Served

  • ISO

    Certified Quality

Committed to Quality
Driven by Innovation

Learn More About US